Clinical Trial Update: Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706 [Phase 1]

View source ↗

Summary

This clinical trial update reports a Phase 1 study evaluating the safety and immunogenicity of Hiltonol (Poly-ICLC) adjuvanted CD40.HIVRI.Env (VRIPRO) in adults…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Hiltonol (Poly-ICLC)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1 | Status: RECRUITING